China Fosun's sale of Gland Pharma could be India's biggest pharma deal

19 December 2022

In what could well be India's biggest pharma deal, China's Fosun Pharma-owned Gland Pharma is on the block. A number of private equity firms have been approached, including Baring Private Equity, Bain Capital, Blackstone, Carlyle, and KKR.

Hyderabad, India-based Gland Pharma (NSE: GLAND) specializes in injectable drugs such as antibiotics, oncology, and cardiology treatments and has a presence in about 60 countries.

Shanghai Fosun Pharmaceutical Group had acquired a 74% stake in Gland for about $1.1 billion in 2017 from an investor group including KKR & Co. It currently owns 57.86% stake in the Indian generic injectable maker.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK